A let-7b binding site SNP in the 3'-UTR of the Bcl-xL gene enhances resistance to 5-fluorouracil and doxorubicin in breast cancer cells

Oncology Letters
Ting WangXiaoyong Lei

Abstract

The development of acquired resistance to chemotherapy is a major obstacle in the successful treatment of cancer. In breast cancer cells, B-cell lymphoma-extra large (Bcl-xL) is involved in the development of resistance to various chemotherapeutic agents; therefore, preliminary biological prediction was performed to identify a putative binding site for let-7b in the 3'-untranslated region (UTR) of the Bcl-xL gene and a single nucleotide polymorphism (SNP) within this binding region. The present study investigated the association between the SNP rs3208684 A>C and chemotherapeutic agent resistance in breast cancer cells. The data indicated that let-7b negatively regulates the expression of Bcl-xL and appears to sensitize MCF-7 cells to the chemotherapeutic agents 5-fluorouracil (5-FU) and doxorubicin. Furthermore, the SNP rs3208684 A>C was demonstrated to enhance Bcl-xL protein expression by disrupting the binding of let-7b to the 3'-UTR of Bcl-xL and, in MCF-7 cells, overexpression of let-7b in the presence of a mutant Bcl-xL 3'-UTR (C allele) significantly increased 5-FU and doxorubicin resistance. Thus, the results of the present study demonstrate that the SNP rs3208684 A>C may upregulate Bcl-xL protein expression and enhance ...Continue Reading

References

Nov 28, 2002·Breast Cancer Research and Treatment·A Paula Simões-WüstUwe Zangemeister-Wittke
Aug 10, 2007·Proceedings of the National Academy of Sciences of the United States of America·Prasun J MishraJoseph R Bertino
May 15, 2008·Carcinogenesis·Kexin ChenWei Zhang
Jun 13, 2008·PLoS Biology·Lieven P BillenDavid W Andrews
Aug 1, 2008·Nature·Daehyun BaekDavid P Bartel
Sep 9, 2008·Trends in Cell Biology·Sarah Roush, Frank J Slack
Sep 26, 2009·Endocrine-related Cancer·Benjamin BoyerinasMarcus E Peter
Mar 20, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Fazlul H SarkarShadan Ali
Mar 30, 2010·Breast Cancer Research : BCR·Elizabeth O'Day, Ashish Lal
Sep 9, 2010·Expert Reviews in Molecular Medicine·Brian LeberDavid W Andrews
Oct 5, 2010·Nature Reviews. Drug Discovery·Ramiro GarzonCarlo M Croce
Feb 1, 2011·Molecular Diagnosis & Therapy·Rachel C Blitzblau, Joanne B Weidhaas
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Nov 16, 2011·Seminars in Oncology·Sukhinder Sandhu, Ramiro Garzon
Jan 25, 2012·Gene Expression·Sarmila Majumder, Samson T Jacob
Feb 18, 2012·Nature·Amaia Lujambio, Scott W Lowe
Jun 14, 2012·Expert Opinion on Therapeutic Targets·William C S Cho
Dec 12, 2012·Advances in Experimental Medicine and Biology·Sooncheol Lee, Shobha Vasudevan
Jan 8, 2013·Cancer Biology & Therapy·Ramesh Singh, Yin-Yuan Mo
Mar 28, 2013·International Journal of Cell Biology·Judith MichelsLorenzo Galluzzi

❮ Previous
Next ❯

Citations

Dec 31, 2015·Nuclear Receptor Signaling·Alexandra L ThomasSteven T Rosen
Dec 29, 2015·Cancer Chemotherapy and Pharmacology·Jin-Feng LvLan Fan
Apr 13, 2017·Frontiers in Genetics·Julien BalzeauJohn P Hagan
Jan 18, 2019·Molecular Therapy. Nucleic Acids·Jia QuJian-Qiang Li

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection

Software Mentioned

GraphPad
GraphPad Prism
PicTar
TargetScan

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.